BP
BioMarin (San Rafael, CA). 2024 revenue ~$2.5B. Rare disease leader. Voxzogo (vosoritide, achondroplasia). Roctavian (valoctocogene roxaparvovec, hemophilia A gene therapy). Naglazyme, Vimizim, Brineura.
BP
BioMarin Pharmaceutical
@bmrn
Joined July 2026
5 Following6 Followers